One-Month Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention With Zotarolimus-Eluting Stents in High-Bleeding-Risk Patients
暂无分享,去创建一个
M. Price | G. Stone | A. Kirtane | T. Nazif | S. Windecker | R. Mehran | D. Kandzari | A. Zaman | D. Simon | Elvin Kedhi | A. Abizaid | S. Worthley | James W Choi | R. Caputo | A. Latib | S. Potluri | T. Lung | B. Mclaurin | T. Tolleson | M. Kanitkar | D. Spriggs | Timothy D Smith | M. Parke | Lilian C Lee | B. McLaurin
[1] Sunil V. Rao,et al. Global Approach to High Bleeding Risk Patients With Polymer-Free Drug-Coated Coronary Stents , 2020, Circulation. Cardiovascular interventions.
[2] Samin K. Sharma,et al. Ticagrelor With or Without Aspirin After PCI: The TWILIGHT Platelet Substudy. , 2020, Journal of the American College of Cardiology.
[3] M. Price,et al. Polymer-based or Polymer-free Stents in Patients at High Bleeding Risk. , 2020, The New England journal of medicine.
[4] Samin K. Sharma,et al. Ticagrelor with or without Aspirin in High-Risk Patients after PCI. , 2019, The New England journal of medicine.
[5] M. Price,et al. Rationale and design of the Onyx ONE global randomized trial: A randomized controlled trial of high-bleeding risk patients after stent placement with 1 month of dual antiplatelet therapy. , 2019, American heart journal.
[6] H. Okayama,et al. Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial. , 2019, JAMA.
[7] M. Price,et al. Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention , 2019, Circulation.
[8] A. Íñiguez,et al. Design and rationale of the Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Standard DAPT Regimen (MASTER DAPT) Study , 2019, American heart journal.
[9] Deepak L. Bhatt,et al. Dual Antiplatelet Therapy Duration Based on Ischemic and Bleeding Risks After Coronary Stenting. , 2019, Journal of the American College of Cardiology.
[10] P. Kolh,et al. [2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS.] , 2018, Kardiologia polska.
[11] S. Cook,et al. Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial , 2018, The Lancet.
[12] J. Cigarroa,et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2016, The Journal of thoracic and cardiovascular surgery.
[13] F. Eberli,et al. Polymer-free Drug-Coated Coronary Stents. , 2016, The New England journal of medicine.
[14] S. Windecker,et al. Antiplatelet therapy duration following bare metal or drug-eluting coronary stents: the dual antiplatelet therapy randomized clinical trial. , 2015, JAMA.
[15] M. Valgimigli,et al. Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates. , 2015, Journal of the American College of Cardiology.
[16] S. Silber,et al. Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation. , 2014, European heart journal.
[17] Jeroen J. Bax,et al. Third universal definition of myocardial infarction. , 2012, Global heart.
[18] Marco Valgimigli,et al. Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report From the Bleeding Academic Research Consortium , 2011, Circulation.
[19] Volker Klauss,et al. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. , 2010, The New England journal of medicine.
[20] S. Yusuf,et al. Fondaparinux compared to enoxaparin in patients with acute coronary syndromes without ST-segment elevation: outcomes and treatment effect across different levels of risk. , 2009, American heart journal.
[21] P. Serruys,et al. Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.
[22] P. Kolh,et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. , 2018, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.